New combo therapy aims to hit MS early and hard
NCT ID NCT07517185
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two strong medications one after the other—rituximab then cladribine—is safe and works well for people with relapsing-remitting multiple sclerosis (MS). Sixty adults aged 18 to 50 with active MS within the last year will receive the treatment and be monitored for 2 years. The main goal is to check for serious side effects, while also tracking brain scans, relapses, and disability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centralsjukhuset Karlstad, Neurologi och Rehabiliteringskliniken
Karlstad, 651 85, Sweden
-
Falu Lasarett, Neurologen
Falun, 79182, Sweden
-
Gävle sjukhus, Neurologmottagningen
Gävle, 80324, Sweden
-
Uppsala University Hospital
Uppsala, 75185, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden MS progression: can brain scans and blood tests predict it?
- Can a new MRI scan reveal the Brain's hidden repair process in MS?
- Walking workouts may sharpen the MS brain — a trial puts it to the test
- Can a simple obstacle course reveal hidden links between fatigue and walking trouble in MS?
- Can sensing wrist position unlock better hand control in MS?
- AI-Powered tool aims to sharpen MS treatment choices